Journal
PHYTOMEDICINE
Volume 95, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.phymed.2021.153856
Keywords
Diabetic nephropathy; Moringa oleifera Lam. seed; renal function; nuclear factor erythroid-derived 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1); glycogen synthase kinase-3 beta (GSK-3 beta)
Ask authors/readers for more resources
Experimental evidence suggests that Moringa oleifera seed extract has therapeutic effects on diabetic nephropathy in rats, potentially through activating the GSK-3 beta and Nrf2/HO-1 pathways to exert antioxidant and anti-renal fibrosis activities.
Background: Moringa oleifera Lam. (M. oleifera) seeds are widely used in traditional folk medicine and as nutritional supplements in the Middle East, Africa, and other regions. Published research showed that M. oleifera seeds (MOS) have pharmacological activities such as blood glucose-lowering, anti-inflammatory, and antitumor effects. However, experimental evidence on the use of MOS to treat diabetic nephropathy and its underlying mechanisms were rarely reported. Purpose: To evaluate the therapeutic effects of MOS extract on the kidneys of high-fat diet (HFD)-fed rats with streptozotocin-induced diabetic nephropathy and reveal its underlying mechanisms. Study design: HFD-fed rats with streptozotocin-induced diabetic nephropathy and high-glucose induced Human Renal Mesangial Cells (HRMC) were used to explore the protective effect of MOS on diabetic nephropathy in vivo and in vitro. Methods:: HRMC were used to preliminarily evaluate the effect of MOS extract under high glucose conditions. For the in vivo study, rats were divided into the following 6 groups (n = 5): normal control group (NC), diabetic nephropathy model group (DN), high dose of MOS-treatment group (DN MOS-H, 200 mg/kg/d); medium dose of MOS-treatment group (DN - MOS-M, 100 mg/kg/d); low dose of MOS-treatment group (DN + MOS-1, 50 mg/kg/d), and metformin-treatment group (DN + MET, 200 mg/kg/d). After 4 weeks of treatment, the damage caused by DN was assessed based on the related parameters of urine and blood. Periodic acid-Schiff (PAS) staining and hematoxylin and eosin (HE) staining were used to assess pathological tissue damage. Immunohistochemistry was used to detect nuclear factor erythroid-derived 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), and phosphorylated-glycogen synthase kinase-3beta (P-GSK-3 beta) levels, whereas western blotting was used to detect Nrf2, HO-1, nephrin, GSK-3 beta, and p-GSK-3 beta levels. Results: MOS extract could inhibit the proliferation of HRMCs induced by high glucose levels. Compared with the rats in the DN group, MOS not only significantly reduced blood glucose levels and oxidative stress in the experimental rats but also improved their kidney function and reduced kidney tissue damage. Additionally, MOS extract increased GSK-3 beta activity and the expression of Nrf2 and HO-1. Conclusions: This study showed that MOS could activate GSK-3 beta and Nrf2/HO-1 pathways to exert antioxidant and anti-renal fibrosis activities, and delay the progression of diabetic nephropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available